Search details
1.
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Nature
; 600(7890): 727-730, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34912120
2.
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Lancet Oncol
; 25(2): 212-224, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38134948
3.
HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.
Br J Cancer
; 130(8): 1316-1323, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38347094
4.
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
Lancet
; 402(10418): 2197-2208, 2023 12 09.
Article
in English
| MEDLINE | ID: mdl-37871604
5.
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Lancet
; 402(10395): 41-53, 2023 07 01.
Article
in English
| MEDLINE | ID: mdl-37331369
6.
Gastric Carcinoma in Autoimmune Gastritis: A Histopathologic and Molecular Study.
Mod Pathol
; 37(6): 100491, 2024 Apr 06.
Article
in English
| MEDLINE | ID: mdl-38588886
7.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38517286
8.
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape : Bertinoro Workshop, November 2022.
Gastric Cancer
; 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38634954
9.
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
Lancet Oncol
; 24(7): 744-756, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37329891
10.
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Br J Cancer
; 128(7): 1391-1399, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36759721
11.
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
Br J Cancer
; 128(5): 877-885, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36482190
12.
Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.
Ann Surg
; 278(3): e540-e548, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-36453261
13.
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
Oncologist
; 28(9): 771-779, 2023 09 07.
Article
in English
| MEDLINE | ID: mdl-37023721
14.
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.
Mod Pathol
; 36(9): 100251, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37355152
15.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Article
in English
| MEDLINE | ID: mdl-36657420
16.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Liver Int
; 43(8): 1803-1812, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37452505
17.
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action.
Gastric Cancer
; 26(6): 958-968, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37382783
18.
KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer.
Future Oncol
; 19(37): 2445-2452, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37701986
19.
The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists' perspective.
Pathologica
; 2023 Jun 14.
Article
in English
| MEDLINE | ID: mdl-37314870
20.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 23(7): 876-887, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35636444